Galectin-3 and the mineralocorticoid receptor antagonist Canrenone in mild heart failure

Francesco Clemenza; Serge Masson; Pier Giulio Conaldi; Daniele Di Carlo; Alessandro Boccanelli; Gian Francesco Mureddu; Lucio Gonzini; Donata Lucci; Aldo P. Maggioni; Andrea Di Lenarda; Enrico B. Nicolis; Massimo Vanasia; Roberto Latini

doi:10.1253/circj.CJ-17-0656

Galectin-3 and the mineralocorticoid receptor antagonist Canrenone in mild heart failure

Francesco Clemenza, Serge Masson, Pier Giulio Conaldi, Daniele Di Carlo, Alessandro Boccanelli, Gian Francesco Mureddu, Lucio Gonzini, Donata Lucci, Aldo P. Maggioni, Andrea Di Lenarda, Enrico B. Nicolis, Massimo Vanasia, Roberto Latini

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Galectin-3 (Gal-3) is involved in collagen deposition and inflammation and is a prognostic biomarker in heart failure (HF). Methods and Results: Gal-3 and other markers of fibrosis or cardiac stress were measured serially in 413 patients with mild HF randomized to the mineralocorticoid receptor antagonist canrenone or placebo to evaluate treatment effect and association with clinical outcome. Gal-3 increased slightly over 6 months in both arms of the study and was associated with clinical endpoints. Conclusions: Although Gal-3 showed prognostic value, the effect of canrenone on clinical outcomes was unaffected by baseline concentrations of biomarkers of fibrosis or cardiac stress.

Original language	English
Pages (from-to)	1543-1546
Number of pages	4
Journal	Circulation Journal
Volume	81
Issue number	10
DOIs	https://doi.org/10.1253/circj.CJ-17-0656
Publication status	Published - Sep 25 2017

Keywords

B-type natriuretic peptide
Clinical trials
Galectin-3
Heart failure
Mineralocorticoid receptor antagonist

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1253/circj.CJ-17-0656

Fingerprint Dive into the research topics of 'Galectin-3 and the mineralocorticoid receptor antagonist Canrenone in mild heart failure'. Together they form a unique fingerprint.

Cite this

Galectin-3 and the mineralocorticoid receptor antagonist Canrenone in mild heart failure. / Clemenza, Francesco; Masson, Serge; Conaldi, Pier Giulio ; Di Carlo, Daniele; Boccanelli, Alessandro; Mureddu, Gian Francesco; Gonzini, Lucio; Lucci, Donata; Maggioni, Aldo P.; Di Lenarda, Andrea; Nicolis, Enrico B.; Vanasia, Massimo; Latini, Roberto.

In: Circulation Journal, Vol. 81, No. 10, 25.09.2017, p. 1543-1546.

Research output: Contribution to journal › Article › peer-review

Clemenza, Francesco ; Masson, Serge ; Conaldi, Pier Giulio ; Di Carlo, Daniele ; Boccanelli, Alessandro ; Mureddu, Gian Francesco ; Gonzini, Lucio ; Lucci, Donata ; Maggioni, Aldo P. ; Di Lenarda, Andrea ; Nicolis, Enrico B. ; Vanasia, Massimo ; Latini, Roberto. / Galectin-3 and the mineralocorticoid receptor antagonist Canrenone in mild heart failure. In: Circulation Journal. 2017 ; Vol. 81, No. 10. pp. 1543-1546.

@article{235ce6312f8c4a1f86f5436799314da7,

title = "Galectin-3 and the mineralocorticoid receptor antagonist Canrenone in mild heart failure",

abstract = "Background: Galectin-3 (Gal-3) is involved in collagen deposition and inflammation and is a prognostic biomarker in heart failure (HF). Methods and Results: Gal-3 and other markers of fibrosis or cardiac stress were measured serially in 413 patients with mild HF randomized to the mineralocorticoid receptor antagonist canrenone or placebo to evaluate treatment effect and association with clinical outcome. Gal-3 increased slightly over 6 months in both arms of the study and was associated with clinical endpoints. Conclusions: Although Gal-3 showed prognostic value, the effect of canrenone on clinical outcomes was unaffected by baseline concentrations of biomarkers of fibrosis or cardiac stress.",

keywords = "B-type natriuretic peptide, Clinical trials, Galectin-3, Heart failure, Mineralocorticoid receptor antagonist",

author = "Francesco Clemenza and Serge Masson and Conaldi, {Pier Giulio} and {Di Carlo}, Daniele and Alessandro Boccanelli and Mureddu, {Gian Francesco} and Lucio Gonzini and Donata Lucci and Maggioni, {Aldo P.} and {Di Lenarda}, Andrea and Nicolis, {Enrico B.} and Massimo Vanasia and Roberto Latini",

year = "2017",

month = sep,

day = "25",

doi = "10.1253/circj.CJ-17-0656",

language = "English",

volume = "81",

pages = "1543--1546",

journal = "Circulation Journal",

issn = "1346-9843",

publisher = "Japanese Circulation Society",

number = "10",

}

TY - JOUR

T1 - Galectin-3 and the mineralocorticoid receptor antagonist Canrenone in mild heart failure

AU - Clemenza, Francesco

AU - Masson, Serge

AU - Conaldi, Pier Giulio

AU - Di Carlo, Daniele

AU - Boccanelli, Alessandro

AU - Mureddu, Gian Francesco

AU - Gonzini, Lucio

AU - Lucci, Donata

AU - Maggioni, Aldo P.

AU - Di Lenarda, Andrea

AU - Nicolis, Enrico B.

AU - Vanasia, Massimo

AU - Latini, Roberto

PY - 2017/9/25

Y1 - 2017/9/25

N2 - Background: Galectin-3 (Gal-3) is involved in collagen deposition and inflammation and is a prognostic biomarker in heart failure (HF). Methods and Results: Gal-3 and other markers of fibrosis or cardiac stress were measured serially in 413 patients with mild HF randomized to the mineralocorticoid receptor antagonist canrenone or placebo to evaluate treatment effect and association with clinical outcome. Gal-3 increased slightly over 6 months in both arms of the study and was associated with clinical endpoints. Conclusions: Although Gal-3 showed prognostic value, the effect of canrenone on clinical outcomes was unaffected by baseline concentrations of biomarkers of fibrosis or cardiac stress.

AB - Background: Galectin-3 (Gal-3) is involved in collagen deposition and inflammation and is a prognostic biomarker in heart failure (HF). Methods and Results: Gal-3 and other markers of fibrosis or cardiac stress were measured serially in 413 patients with mild HF randomized to the mineralocorticoid receptor antagonist canrenone or placebo to evaluate treatment effect and association with clinical outcome. Gal-3 increased slightly over 6 months in both arms of the study and was associated with clinical endpoints. Conclusions: Although Gal-3 showed prognostic value, the effect of canrenone on clinical outcomes was unaffected by baseline concentrations of biomarkers of fibrosis or cardiac stress.

KW - B-type natriuretic peptide

KW - Clinical trials

KW - Galectin-3

KW - Heart failure

KW - Mineralocorticoid receptor antagonist

UR - http://www.scopus.com/inward/record.url?scp=85030109558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030109558&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-17-0656

DO - 10.1253/circj.CJ-17-0656

M3 - Article

AN - SCOPUS:85030109558

VL - 81

SP - 1543

EP - 1546

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 10

ER -